Abstract
So far, therapeutics focusing on reducing levels of amyloid beta for treatment of Alzheimer’s disease have not been successful in completing clinical trials to come to market, suggesting the need of a wider perspective and the consideration of novel targets of intervention to slow or halt the progression of this disease. One such target is soluble amyloid beta in oligomeric forms, which have been demonstrated to bind with high affinity to zinc released during synaptic activity. This review considers the interaction of AβO and zinc and the role of zinc in neurotransmission along with possible neurotoxic effects of this interaction. Finally, it also discusses recent experimental data in animal models that have translated into potential treatments for AD based on the modulation of hyperexcitability and zinc homeostasis.
Keywords: Amyloid beta, oligomers, zinc, synapses, Alzheimer’s disease.
Current Pharmaceutical Design
Title:Disruption of Zinc Neuromodulation by Aß Oligomers : Therapeutic Implications
Volume: 20 Issue: 15
Author(s): Emily C. Vogler and Jorge Busciglio
Affiliation:
Keywords: Amyloid beta, oligomers, zinc, synapses, Alzheimer’s disease.
Abstract: So far, therapeutics focusing on reducing levels of amyloid beta for treatment of Alzheimer’s disease have not been successful in completing clinical trials to come to market, suggesting the need of a wider perspective and the consideration of novel targets of intervention to slow or halt the progression of this disease. One such target is soluble amyloid beta in oligomeric forms, which have been demonstrated to bind with high affinity to zinc released during synaptic activity. This review considers the interaction of AβO and zinc and the role of zinc in neurotransmission along with possible neurotoxic effects of this interaction. Finally, it also discusses recent experimental data in animal models that have translated into potential treatments for AD based on the modulation of hyperexcitability and zinc homeostasis.
Export Options
About this article
Cite this article as:
Vogler C. Emily and Busciglio Jorge, Disruption of Zinc Neuromodulation by Aß Oligomers : Therapeutic Implications, Current Pharmaceutical Design 2014; 20 (15) . https://dx.doi.org/10.2174/13816128113199990510
DOI https://dx.doi.org/10.2174/13816128113199990510 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Valproate Induced Acute Pancreatitis - A Unique Case Report
Current Drug Safety Pharmacodynamics of Memantine: An Update
Current Neuropharmacology Metabolic Targeting of Cancers: From Molecular Mechanisms to Therapeutic Strategies
Current Medicinal Chemistry Synthesis and Anticonvulsant Activity Evaluation of Some 1-alkoxy-4-(1H- 1,2,4-triazol-1-yl)phthalazines
Letters in Drug Design & Discovery Genome-wide Membrane Protein Structure Prediction
Current Genomics Patent Selections
Recent Patents on Computer Science Subject Index to Volume 1
Medicinal Chemistry Reviews - Online (Discontinued) Are Antipsychotics Useful in the Treatment of Anorexia Nervosa? A Review of the Literature
Current Psychopharmacology TMS - A New Neuroimaging Combinational Tool to Study Brain Function
Current Medical Imaging Drugs in Newborn Resuscitation: The More We Learn the Least We Use
Current Medicinal Chemistry Rationale Design, Synthesis, and Pharmacological Evaluation of Isatin Analogues as Antiseizure Agents
Letters in Drug Design & Discovery Febrile Infection-Related Epilepsy Syndrome (FIRES): An Overview of Treatment and Recent Patents
Recent Patents on Inflammation & Allergy Drug Discovery The Current WHO Classification of Tumours of the Central Nervous System: Histopathology and Additional Diagnostic Methods
Current Medical Imaging Computational Study and Synthesis of a New Class of Anticonvulsants with 6 Hz Psychomotor Seizure Test Activity: 2-(1,3-benzodioxol-5-yloxy)- N'-[substituted]-acetohydrazides
Medicinal Chemistry Cross-Cultural Comparison of Mild Cognitive Impairment between China and USA
Current Alzheimer Research The Menstrual Cycle and Drug Metabolism
Current Drug Metabolism Cyclooxygenase-2 Inhibitors as a Therapeutic Target in Inflammatory Diseases
Current Medicinal Chemistry Recent Approaches for Studying the Role of Glia
CNS & Neurological Disorders - Drug Targets Analysis of Electrical Brain Waves in Neurotoxicology: Gamma- Hydroxybutyrate
Current Neuropharmacology Biochemical Markers for Brain Injury Monitoring in Children with or without Congenital Heart Diseases
CNS & Neurological Disorders - Drug Targets